0.9851
price up icon1.34%   0.0131
 
loading
前日終値:
$0.972
開ける:
$0.98
24時間の取引高:
32,462
Relative Volume:
0.25
時価総額:
$34.72M
収益:
-
当期純損益:
$-9.16M
株価収益率:
-1.7282
EPS:
-0.57
ネットキャッシュフロー:
$-8.75M
1週間 パフォーマンス:
+3.68%
1か月 パフォーマンス:
-1.50%
6か月 パフォーマンス:
-4.77%
1年 パフォーマンス:
-18.60%
1日の値動き範囲:
Value
$0.97
$1.00
1週間の範囲:
Value
$0.9401
$1.04
52週間の値動き範囲:
Value
$0.75
$1.6899

Renovorx Inc Stock (RNXT) Company Profile

Name
名前
Renovorx Inc
Name
セクター
Healthcare (1153)
Name
電話
408-800-2649
Name
住所
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Name
職員
10
Name
Twitter
Name
次回の収益日
2024-08-15
Name
最新のSEC提出書
Name
RNXT's Discussions on Twitter

RNXT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RNXT
Renovorx Inc
0.9876 34.72M 0 -9.16M -8.75M -0.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
506.10 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
570.41 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
631.10 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
258.76 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.92 24.70B 3.81B -644.79M -669.77M -6.24

Renovorx Inc (RNXT) 最新ニュース

pulisher
10:43 AM

RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer T - GuruFocus

10:43 AM
pulisher
08:39 AM

Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx'S Ongoing Phase III Tiger-Pac Clinical Trial - marketscreener.com

08:39 AM
pulisher
08:30 AM

Johns Hopkins Medicine Accelerates RenovoRx's Breakthrough Pancreatic Cancer Trial Progress - Stock Titan

08:30 AM
pulisher
05:23 AM

RenovoRx (NASDAQ:RNXT) Price Target Raised to $11.00 at Ascendiant Capital Markets - Defense World

05:23 AM
pulisher
Apr 27, 2025

RenovoRx Reports Initial Revenue and Clinical Trial Progress - MSN

Apr 27, 2025
pulisher
Apr 17, 2025

RenovoRx CMO Makes Bold Stock Purchase! - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 16, 2025

RenovoRx ramps up production of FDA-cleared RenovoCath By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment | Newswise - Newswise

Apr 16, 2025
pulisher
Apr 16, 2025

RenovoRx CEO Shaun Bagai acquires $6,821 in common stock - Investing.com Australia

Apr 16, 2025
pulisher
Apr 16, 2025

RenovoRx CEO Shaun Bagai acquires $6,821 in common stock By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 16, 2025

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community - BioSpace

Apr 16, 2025
pulisher
Apr 16, 2025

RenovoRx ramps up production of FDA-cleared RenovoCath - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

Medical Device Maker RenovoRx Eyes $400M Market With Surging RenovoCath Demand - Stock Titan

Apr 16, 2025
pulisher
Apr 14, 2025

RenovoRx CMO Makes Bold Stock Purchase - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock By Investing.com - Investing.com India

Apr 14, 2025
pulisher
Apr 14, 2025

RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock - Investing.com

Apr 14, 2025
pulisher
Apr 11, 2025

RenovoRx CMO Agah Ramtin purchases $24,399 in common stock By Investing.com - Investing.com India

Apr 11, 2025
pulisher
Apr 10, 2025

Top Executives Make Bold Moves with RenovoRx Stock Purchases! - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock - Investing.com Australia

Apr 10, 2025
pulisher
Apr 10, 2025

RenovoRx Executives Increase Their Holdings - TradingView

Apr 10, 2025
pulisher
Apr 10, 2025

RenovoRx CMO Agah Ramtin purchases $24,399 in common stock - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

RenovoRx CEO Shaun Bagai acquires $8,300 in common stock By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

RenovoRx CEO Shaun Bagai acquires $8,300 in common stock - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

Renovorx director Marton Laurence buys $10,218 in common stock By Investing.com - Investing.com UK

Apr 10, 2025
pulisher
Apr 09, 2025

RenovoRx CMO Makes a Bold Move with Major Stock Purchase - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

RenovoRx Executives Increase Stake in Company - TradingView

Apr 09, 2025
pulisher
Apr 09, 2025

Renovorx director Marton Laurence buys $10,218 in common stock - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Renovorx chief medical officer Agah Ramtin buys $21,840 in shares - Investing.com Australia

Apr 09, 2025
pulisher
Apr 09, 2025

Renovorx chief medical officer Agah Ramtin buys $21,840 in shares By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 08, 2025

RenovoRx CEO Shaun Bagai purchases $8,300 in company stock By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

RenovoRx CEO Shaun Bagai purchases $8,300 in company stock - Investing.com

Apr 08, 2025
pulisher
Apr 07, 2025

RenovoRx stock hits 52-week low at $0.77 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

RenovoRx stock hits 52-week low at $0.77 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 06, 2025

HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World

Apr 06, 2025
pulisher
Apr 04, 2025

H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa

Apr 04, 2025

Renovorx Inc (RNXT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Renovorx Inc (RNXT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Bagai Shaun
Chief Executive Officer
Apr 15 '25
Buy
0.91
7,500
6,821
320,040
Agah Ramtin
Chief Medical Officer
Apr 11 '25
Buy
0.80
20,000
16,000
1,098,460
Kocak Ron
VP Controller and PAO
Apr 10 '25
Buy
0.79
6,500
5,135
12,595
Kocak Ron
VP Controller and PAO
Apr 09 '25
Buy
0.80
6,000
4,800
6,095
Kocak Ron
VP Controller and PAO
Apr 08 '25
Buy
0.80
95
76
95
Agah Ramtin
Chief Medical Officer
Apr 09 '25
Buy
0.81
30,000
24,399
1,078,460
Bagai Shaun
Chief Executive Officer
Apr 09 '25
Buy
0.83
10,000
8,300
312,540
Marton Laurence
Director
Apr 08 '25
Buy
0.85
12,050
10,218
45,684
Agah Ramtin
Chief Medical Officer
Apr 08 '25
Buy
0.84
26,000
21,840
1,048,460
Bagai Shaun
Chief Executive Officer
Apr 07 '25
Buy
0.83
10,000
8,300
302,540
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
大文字化:     |  ボリューム (24 時間):